Logo image of OCGN

OCUGEN INC (OCGN) Stock Fundamental Analysis

NASDAQ:OCGN - Nasdaq - US67577C1053 - Common Stock - Currency: USD

0.68  -0.02 (-2.88%)

After market: 0.6899 +0.01 (+1.46%)

Fundamental Rating

2

Taking everything into account, OCGN scores 2 out of 10 in our fundamental rating. OCGN was compared to 572 industry peers in the Biotechnology industry. Both the profitability and financial health of OCGN have multiple concerns. OCGN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

OCGN had negative earnings in the past year.
In the past year OCGN has reported a negative cash flow from operations.
OCGN had negative earnings in each of the past 5 years.
OCGN had a negative operating cash flow in each of the past 5 years.
OCGN Yearly Net Income VS EBIT VS OCF VS FCFOCGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of OCGN (-99.44%) is worse than 75.49% of its industry peers.
With a Return On Equity value of -151.59%, OCGN is not doing good in the industry: 64.65% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -99.44%
ROE -151.59%
ROIC N/A
ROA(3y)-75.93%
ROA(5y)-94.74%
ROE(3y)-104.39%
ROE(5y)-131.26%
ROIC(3y)N/A
ROIC(5y)N/A
OCGN Yearly ROA, ROE, ROICOCGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 1K 1.5K

1.3 Margins

OCGN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OCGN Yearly Profit, Operating, Gross MarginsOCGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20K -40K -60K -80K

More info and screens

3

2. Health

2.1 Basic Checks

OCGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OCGN has more shares outstanding
OCGN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for OCGN is higher compared to a year ago.
OCGN Yearly Shares OutstandingOCGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M
OCGN Yearly Total Debt VS Total AssetsOCGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -4.44, we must say that OCGN is in the distress zone and has some risk of bankruptcy.
OCGN has a Altman-Z score (-4.44) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.04 indicates that OCGN is not too dependend on debt financing.
The Debt to Equity ratio of OCGN (0.04) is worse than 61.28% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z -4.44
ROIC/WACCN/A
WACC9.42%
OCGN Yearly LT Debt VS Equity VS FCFOCGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M

2.3 Liquidity

OCGN has a Current Ratio of 2.58. This indicates that OCGN is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of OCGN (2.58) is worse than 71.23% of its industry peers.
OCGN has a Quick Ratio of 2.58. This indicates that OCGN is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.58, OCGN is not doing good in the industry: 69.98% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.58
Quick Ratio 2.58
OCGN Yearly Current Assets VS Current LiabilitesOCGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

OCGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.16%, which is quite impressive.
The Revenue has been growing by 432.39% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)45.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.67%
Revenue 1Y (TTM)N/A
Revenue growth 3Y432.39%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

OCGN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.32% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y15%
EPS Next 2Y-3.08%
EPS Next 3Y1.44%
EPS Next 5Y12.32%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OCGN Yearly Revenue VS EstimatesOCGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
OCGN Yearly EPS VS EstimatesOCGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OCGN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OCGN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OCGN Price Earnings VS Forward Price EarningsOCGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OCGN Per share dataOCGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.08%
EPS Next 3Y1.44%

More info and screens

0

5. Dividend

5.1 Amount

OCGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OCUGEN INC

NASDAQ:OCGN (2/21/2025, 8:00:01 PM)

After market: 0.6899 +0.01 (+1.46%)

0.68

-0.02 (-2.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-08 2024-11-08/bmo
Earnings (Next)03-05 2025-03-05/amc
Inst Owners24.75%
Inst Owner Change-96.34%
Ins Owners0.95%
Ins Owner Change-5.24%
Market Cap198.10M
Analysts82
Price Target6.63 (875%)
Short Float %20.47%
Short Ratio12.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.27%
Min EPS beat(2)8.08%
Max EPS beat(2)26.47%
EPS beat(4)4
Avg EPS beat(4)27.97%
Min EPS beat(4)8.08%
Max EPS beat(4)54.75%
EPS beat(8)6
Avg EPS beat(8)19.67%
EPS beat(12)7
Avg EPS beat(12)-274.46%
EPS beat(16)7
Avg EPS beat(16)-237.24%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)18.18%
PT rev (3m)18.18%
EPS NQ rev (1m)1.56%
EPS NQ rev (3m)1.56%
EPS NY rev (1m)1.23%
EPS NY rev (3m)6.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)31.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 19.16
P/FCF N/A
P/OCF N/A
P/B 4.88
P/tB 4.88
EV/EBITDA N/A
EPS(TTM)-0.17
EYN/A
EPS(NY)-0.25
Fwd EYN/A
FCF(TTM)-0.17
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0.04
BVpS0.14
TBVpS0.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -99.44%
ROE -151.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-75.93%
ROA(5y)-94.74%
ROE(3y)-104.39%
ROE(5y)-131.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 394.95%
Cap/Sales 58.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.58
Quick Ratio 2.58
Altman-Z -4.44
F-Score4
WACC9.42%
ROIC/WACCN/A
Cap/Depr(3y)960.82%
Cap/Depr(5y)648.49%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.67%
EPS Next Y15%
EPS Next 2Y-3.08%
EPS Next 3Y1.44%
EPS Next 5Y12.32%
Revenue 1Y (TTM)N/A
Revenue growth 3Y432.39%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y16.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.03%
OCF growth 3YN/A
OCF growth 5YN/A